Portfolio  /  Pharmaceutical  /  Xeomin  /

Xeomin

Xeomin

* FDA approved in 2010 for use in the United States for cervical dystonia and blepharospasm in adults. * FDA approved in 2015 for use in the United States for upper limb spasticity in adults. * Approved in Europe for cervical dystonia and blepharospasm since 2005 and approved for post-stroke ULS in Europe since 2009. * Approved in Canada for cervical dystonia, blepharospasm, and ULS since 2009. * Used in 49 countries worldwide. * Studied in clinical trials worldwide, which involved: * More than 400 adult patients with upper limb spasticity,including patients who had been previously treated and patients who were new to neurotoxin therapy * Nearly 600 patients with cervical dystonia * Nearly 400 patients with blepharospasm


Newsletter


Subscribe our latest news and events.

Get in Touch


  • +98 21 86085141
  • info (at) medisaara.com
  • Sat-Thu 9:00 am-6:00 pm

Number 21, Jooybar Alley, Shad St, Molla Sadra St, Tehran - Iran

Terms of Use

Copyright © 2020 Medisa ara gostar All rights reserved.